Skip to main content

Table 2 Tumor response of the investigated patients with advanced esophageal squamous cell carcinoma as determined based on CT scans

From: Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Response Treatment groups
Irinotecan plus S-1 [cases (%)] S-1 monotherapy [cases (%)]
Total 61 62
CR 1 (1.6) 0 (0.0)
PR 14 (22.9) 6 (9.7)
SD 20 (32.8) 16 (25.8)
PD 14 (23.0) 26 (41.9)
Not assessable 12 (19.7) 14 (22.6)
  1. CT computed tomography, CR complete response, PR partial response, SD stable disease, PD progressive disease